Arch Pharmalabs Profile
Key Indicators
- Authorised Capital ₹ 3,000.00 Cr
- Paid Up Capital ₹ 156.48 Cr
- Company Age 31 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5,668.24 Cr
- Satisfied Charges ₹ 311.84 Cr
- Revenue Growth 2.29%
- Profit Growth 112.30%
- Ebitda 1.64%
- Net Worth 39.39%
- Total Assets 4.17%
About Arch Pharmalabs
Arch Pharmalabs Limited (APL) is a leading Public Limited Indian Non-Government Company incorporated in India on 02 April 1993 and has a history of 31 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Avant Papers Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3,000.00 Cr and a paid-up capital of Rs 156.48 Cr.
The company currently has active open charges totaling ₹5,668.24 Cr. The company has closed loans amounting to ₹311.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Arch Pharmalabs Limited India are Vikas Kedia as COMPANY SECRETARY and Rajendra Kaimal as Cfo. Rajendra Kaimal, Ajit Kamath, Ashish Ujagare, and One other member serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231MH1993PLC150891
- Company No.
150891
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Apr 1993
- Date of AGM
29 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Arch Pharmalabs Limited offer?
Arch Pharmalabs Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Cancer Injection, Common Disease Medicines, Injectable Products, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Cardiovascular Drugs & Medication, Diabetes Medicine, Brain & Nervous System Drugs.
Who are the key members and board of directors at Arch Pharmalabs?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajit Kamath  | Managing Director | 01-Nov-2003 | Current |
| Vikas Kedia | Company Secretary | 18-Nov-2017 | Current |
| Rajendra Kaimal | CFO | 30-May-2019 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajendra Kaimal | Whole-Time Director and Cfo | 01-Nov-2003 | Current |
| Ashish Ujagare | Whole-Time Director | 14-Jun-2018 | Current |
| Sunil Pitroda | Director | 02-May-2017 | Current |
Financial Performance of Arch Pharmalabs.
Arch Pharmalabs Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.29% increase. The company also saw a substantial improvement in profitability, with a 112.3% increase in profit. The company's net worth Soared by an impressive increase of 39.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arch Pharmalabs?
In 2023, Arch Pharmalabs had a promoter holding of 58.13% and a public holding of 41.87%. The company had 3 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arch Pharmachem LtdRajendra Kaimal and Ajit Kamath are mutual person
- Arch Life Sciences Limited
Rajendra Kaimal and Ajit Kamath are mutual person
Vitalife Pharma LimitedRajendra Kaimal, Ajit Kamath and 1 more are mutual person
- Arch Agro Industries Private Limited
Rajendra Kaimal and Ajit Kamath are mutual person
- Amra Renal Care Limited
Rajendra Kaimal and Ajit Kamath are mutual person
- Arch Finechemicals Limited
Rajendra Kaimal and Ajit Kamath are mutual person
Charges (Loans)
₹5,668.24 Cr
₹311.84 Cr
Charges Breakdown by Lending Institutions
- Others : 5443.74 Cr
- Axis Trustee Services Limited : 120.00 Cr
- Canara Bank : 50.00 Cr
- State Bank Of Indore : 34.50 Cr
- Centurion Bank Of Punjab : 10.00 Cr
- Others : 10.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2022 | Others | ₹32.00 Cr | Open |
| 20 Jul 2021 | Others | ₹0.50 M | Open |
| 27 May 2021 | Others | ₹200.00 Cr | Open |
| 04 Dec 2017 | Others | ₹200.00 Cr | Open |
| 27 Sep 2013 | Others | ₹582.30 Cr | Open |
How Many Employees Work at Arch Pharmalabs?
Arch Pharmalabs has a workforce of 412 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arch Pharmalabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arch Pharmalabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
